Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Phase 1/2 Active not recruiting 54 enrolled COUR Pharmaceutical Development Company, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.

Timeline

Start: 2024-05-30
Primary completion: 2026-06
Completion: 2026-08

Publications

G Brew S, Frey M, P McCarthy D, Elhofy A, Nowak RJ. Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial. BMJ Neurol Open. 2024 Dec 18;6(2):e000836. doi: 10.1136/bmjno-2024-000836. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CNP-106	Peptide	200 ml	Intravenous

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Summary

Timeline

Publications

Drugs

Indications